CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Recruiting· 44 target
Drug / intervention
WTX212Adrug
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Aged 18 to 75 years old
  • ✓Histopathology diagnosed unresectable or metastatic solid tumors who have failed systemic treatment or have no effective standard treatment, or who are unwilling to accept standard treatment or are not suitable for standard treatment
  • ✓Expected life ≥ 3 months
  • ✓Contraception required from informed consent until 3 months after last dose
Key exclusion· 8
  • ✕Other serious medical diseases including uncontrolled diabetes, active peptic ulcer, active bleeding, uncontrollable or serious cardiovascular diseases
  • ✕Pleural and ascitic fluids with clinical symptoms requiring repeated drainage
  • ✕Previous or recent history of pulmonary fibrosis, severe lung function damage from pneumoconiosis, radiation pneumonia, or drug-related pneumonia
  • ✕History of adverse events related to IO drugs requiring permanent cessation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06026605
NCT06026605Early Ph 1RecruitingOn TrackUpdated 17mo ago
CompareCT.gov

A MulticenterOpen LableDose Escalat Tion and Dose Expansion Clinical Study to Evaluate the Safety, Tolerance and Ini Itial Effectiveness of WTX212A Injection in Patients with Unresectable or Metasta Atic Advanced Solid Tumors

Zhejiang University·interventional·Posted Sep 7, 2023·Updated Jan 16, 2025

In Brief

A Early Phase 1 clinical trial evaluating WTX212A for Unresectable or Metastatic Advanced Solid Tumors. Currently recruiting, targeting 44 participants across 1 site.

Detailed Summary

This trial is a multi-center, open-label investigator-initiated clinical study (IIT) to evaluate the safety, pharmacokinetics, pharmacodynamics and effectiveness of WTX212A injection in the treatment of patients with unresectable or metastatic advanced solid tumors who failed in previous systematic therapy. The study was divided into two phases: dose escalation and dose expansion

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable or Metastatic Advanced Solid Tumors
CountriesChina
Collaborators--

Timeline

Early Ph 1Recruiting
202420252026
First PostedSep 7, 2023
Enrollment StartAug 25, 2023
Primary CompletionAug 30, 2026
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 2.8 years agoPrimary completion in 2 months

Interventions

WTX212Adrug

WTX212A infusion once every 21 days